Advocacy - Comment Letter

AACC Joins AMP in Support of HHS Policy Change on LDTs

View Letter

Dear Secretary Azar:

The American Association for Clinical Chemistry (AACC) and Association for Molecular Pathology (AMP) represent physicians, doctoral scientists, medical technologists, and other laboratory professionals dedicated to delivering high quality medical care by providing patients and their treating healthcare provider with vital information gleaned, in part, from laboratory testing services. We support the U.S. Department of Health and Human Services (HHS)’s decision to rescind all guidance and other informal documents and communications concerning premarket review of laboratory developed testing procedures (LDPs). We commend the Department for providing greater clarity on this issue and eliminating duplicative regulatory requirements for LDPs.

We agree that the Food and Drug Administration (FDA) must employ formal notice and comment rulemaking, as specified under the Administrative Procedures Act, before seeking to impose any new and significant regulatory requirements on clinical laboratories, hospitals, and health care providers. The laboratory community first raised this issue in 2014 when the FDA issued draft guidance that would extend agency oversight to LDPs— duplicating existing Clinical Laboratory Improvement Amendments (CLIA) regulations promulgated by the Centers for Medicaid & Medicare Services (CMS).

The HHS FAQ document on LDPs accurately details the requirements clinical laboratories must meet to perform these tests, such as validating the test within its clinical context, passing regular inspections and proficiency testing, adopting a robust quality management system, and employing appropriately licensed or credentialed laboratory personnel. We are confident that a CLIA-based regulatory system will continue to ensure that patients are given high quality health information to inform not only care related to COVID-19, but also cancer, rare diseases, other infectious diseases, and more.

Once again, thank you for providing clarity and streamlining regulatory requirements for the many healthcare professionals that depend on and use laboratory developed testing procedures in their clinical practice. If you have questions, please contact Vince Stine, PhD at [email protected] or Tara Burke, PhD at [email protected].


American Association for Clinical Chemistry
Association for Molecular Pathology